Ginkgo Bioworks Holdings (DNA) Net Income towards Common Stockholders (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Net Income towards Common Stockholders of -$6.5 million for Q1 2026, up 91.92% on a QoQ basis from -$80.8 million in Q4 2025, and up 14.63% year-over-year from -$5.7 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$6.5 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.63% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$228.3 million (up 41.27% YoY) and the FY2025 annual result came in at -$312.8 million, up 42.83% from the prior year.
- Net Income towards Common Stockholders was -$6.5 million for Q1 2026 at Ginkgo Bioworks Holdings, up from -$80.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$6.5 million in Q1 2026 and bottomed at -$670.6 million in Q2 2022.
- A 5-year average of -$222.4 million and a median of -$173.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 1131.22% — and 2025, when it soared 95.39%.
- Ginkgo Bioworks Holdings' Net Income towards Common Stockholders stood at -$173.1 million in 2022, then decreased by 22.31% to -$211.7 million in 2023, then jumped by 49.2% to -$107.5 million in 2024, then climbed by 24.91% to -$80.8 million in 2025, then jumped by 91.92% to -$6.5 million in 2026.
- Business Quant data shows DNA's Net Income towards Common Stockholders at -$6.5 million in Q1 2026, -$80.8 million in Q4 2025, and -$80.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Ginkgo Bioworks Holdings | 441.96 Mn | 298.10 Mn | 16.38 Mn | -6.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.53 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -7.65 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -173.08 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -590.51 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |
| Jun 30, 2021 | -54.46 Mn |